June 2026 Life-Sciences Hiring: Who Is Hiring, What Roles Are Hot, and Where the Tech Stack Is Going
A data-driven analysis of 6,804 active life-sciences job postings indexed in June 2026 across 138 companies — top hirers, in-demand roles, tech-stack keywords, geographic spread, and what the hiring data tells us about the state of biotech and pharma employment in mid-2026.
The mid-2026 life-sciences hiring market is doing something the “biotech is in a deep freeze” narrative does not predict. Across 6,804 active job postings indexed across 138 companies in June 2026, Big Pharma is hiring in volume, AI/ML mentions are real but pre-inflection, R still dominates Python for statistical computing, and one European contract-research conglomerate is running what looks like a coordinated global capacity-expansion campaign. Here is what the data shows.
1. Headline Numbers
The June 2026 cohort we analyzed — drawn from public company career pages and hiring listings across the life-sciences sector — produced:
- 6,804 active job postings indexed in June 2026.
- 138 distinct hiring companies represented.
- 258 postings with full job descriptions (~3.8% of total) — most postings expose only the title and location, not the full description.
- 2,510 of the 6,804 (37%) came from a single company’s hiring site (Eurofins CDMO).
- ~17% of all roles are at mid-senior or above (Senior, Lead/Principal/Staff, Director/Head/VP).
- ~1% of roles explicitly mention Remote or Hybrid.
The top-of-funnel number — 6,804 active roles in a single month from a curated life-sciences index — is a useful baseline for where the industry stands entering H2 2026.
2. Who Is Hiring
2.1 The Single-Largest Hirer: Eurofins CDMO
The June 2026 standout is Eurofins CDMO with 2,510 unique active roles — verified-unique across URLs and titles. What makes this unusual is the geographic spread:
| Country | June-active Eurofins roles |
|---|---|
| United States | 585 |
| France | 585 |
| India | 271 |
| Germany | 199 |
| Netherlands | 161 |
| United Kingdom | 63 |
| Vietnam | 61 |
| Canada | 60 |
| Brazil | 54 |
| Belgium | 53 |
| Spain | 52 |
| Poland | 47 |
| Italy | 45 |
| Denmark | 30 |
| Ireland | 29 |
| Australia | 24 |
| Singapore | 23 |
| Switzerland | 22 |
| Portugal | 17 |
| China | 11 |
| Hungary, Slovakia, Austria, Finland, Sweden, Romania, Norway, New Zealand, Japan | 5–10 each |
Titles appear in Japanese, French, German, Norwegian, Vietnamese, Czech, Hungarian, Slovak, Turkish, Dutch, Danish, Italian, Portuguese, and Spanish — Eurofins is hiring in their native language at each site, consistent with localized laboratory and CDMO operations. Top title concentrations sit in lab/QC roles: Sample Receiving Technician, Laboratory Technologist, Analytical Scientist, Bioanalytical Scientist, QC Analyst.
The bet: Eurofins is running a coordinated global capacity-expansion campaign in mid-2026 — either tied to a contract win, a footprint expansion, or a mass backfill. A life-sciences conglomerate hiring 2,500+ simultaneously across 30 countries is unusual.
2.2 The Big-Pharma Top 10 (Career Sites)
Excluding the single-source-dominated Eurofins bucket, the cleanest company-level signal comes from the large-pharma career sites (where the Big-Pharma names publish their openings). In order of June-active hiring volume:
| Rank | Company | June-active roles |
|---|---|---|
| 1 | Roche | 199 |
| 2 | Novartis | 193 |
| 3 | AstraZeneca | 178 |
| 4 | Takeda | 168 |
| 5 | Pfizer | 163 |
| 6 | Sanofi | 143 |
| 7 | Tempus | 134 |
| 8 | Illumina | 132 |
| 9 | Vertex Pharmaceuticals | 122 |
| 10 | Qiagen | 110 |
Every Big-Pharma name on this list has 100+ actively-posted June 2026 roles. That contradicts the “Big Pharma is contracting” narrative — large pharmas are still expanding headcount materially in mid-2026. Mid-cap names with serious activity: Tempus (oncology data platform), Illumina (sequencing), Vertex (cystic fibrosis / sickle cell), Qiagen (molecular sample technologies).
2.3 The Single-Source Caveat
AbbVie appears with 789 roles in the June cohort, but 764 of those are listed through a single third-party hiring site without per-posting URL validation in our dataset. The number is plausible — AbbVie is one of the largest pharmas by market cap — but treat as an upper bound until the per-row source is reconciled.
2.4 Below the Top 10
After the Big-Pharma names and Eurofins, the next tier of mid-30s-to-low-100s active roles includes: BioEclipse Therapeutics, Affinity Biosciences, Eli Lilly, Cambridge Bioscience, West Pharmaceutical, iRhythm Technologies, Siegfried, Zoetis, Regeneron, WestPharma, GenScript, AbClon. This is a healthy mid-cap mix — diagnostics, CDMO, specialty pharma, generics, and instruments.
3. What Roles Are Hot
3.1 Seniority Mix
| Seniority | Roles | Share |
|---|---|---|
| Individual Contributor / Unspecified | 5,300 | 77.9% |
| Senior | 828 | 12.2% |
| Associate / Assistant | 289 | 4.2% |
| Lead / Principal / Staff | 155 | 2.3% |
| Director / Head / VP | 130 | 1.9% |
| Manager | 33 | 0.5% |
| Intern | 35 | 0.5% |
| Junior | 34 | 0.5% |
Reading: IC-heavy but not IC-only. ~17% of all June-active roles are at mid-senior or above. Manager+ total is 318 (4.7%) — a real leadership-pipeline signal. The Intern + Junior + Associate/Assistant bucket together (358, 5.3%) represents the entry-tier pipeline.
3.2 Departments
Where department is tagged (48% of rows):
| Department | Count |
|---|---|
| Testing & Laboratory | 1,589 |
| IT | 243 |
| Commercial & Customer Care | 156 |
| Quality Assurance | 115 |
| Finance | 104 |
| Administrative Support | 79 |
| General Management | 62 |
| Consulting & Operational Excellence | 55 |
| R&D | 52 |
| Operations | 42 |
| Engineering | 41 |
| Logistics | 38 |
| HR | 35 |
Reading: where department IS populated, Testing & Laboratory dominates by 6.5x — Eurofins + CRO/QC labs drive this. IT is a distant second, then Quality Assurance at #4. The unstated reality is that 52% of rows have no department tag (most large-pharma postings only surface title + location) — so the “Testing & Laboratory is dominant” headline is partially a sample artifact.
3.3 Recurring Titles
No single title dominates the corpus — the top-recurring titles are Project Manager (5), Account Manager (5), Senior Software Engineer (4), Executive Assistant (4), Senior HR Business Partner (3), Senior Cloud Engineer (3), Senior Accountant (3), Regulatory Affairs Specialist (3), Regulatory Affairs Manager (3). Regulatory Affairs (Specialist + Manager combined = 6) is the single strongest functional cluster by title repetition.
3.4 What Big-Pharma Is Hiring For (by Title Sample)
Looking at the career sites of the Big 6 (Roche, Novartis, AZ, Takeda, Pfizer, Sanofi) plus Regeneron:
- Roche: Vice President, US Medical Neurology; Therapeutic Area Manager (TAM), Hematology – Virginia Ecosystem; Technical Development Principal Scientist – Computational Biophysics; Validation System Business Process Owner; Senior Manager Business Strategy & Operations
- Regeneron: Sr Staff Engineer, Synthetic and Bioconjugation Scale-Up Technologies; Sr. Manager Workday; Senior Manager EDC Development; Senior Manager, Predictive Analytics; Principal Supply Analyst – Kinaxis Maestro
- Sanofi: Senior Director, Federal Government Affairs; Senior Manager, Pharmacovigilance Operations; Senior Manager Cloud Platform Engineer
- Tempus: AI/ML-heavy oncology-data platform roles
- Vertex: CF / sickle-cell program expansion roles
The pattern: Big-Pharma hiring in mid-2026 is specialty-clinical + computational/AI + supply-chain-modernization, not generic sales/clerical expansion. The titles that recur are senior, technical, and program-specific.
4. The Tech-Stack / Keyword Signal
Across the 258 June-active jobs with full descriptions, we ran a 63-term regex library against the description text and counted occurrences. The top results:
| Mentions | Term |
|---|---|
| 65 | R (programming) |
| 39 | FDA |
| 33 | Clinical Trials |
| 29 | Python |
| 24 | GMP |
| 18 | Machine Learning |
| 18 | GCP (mostly Good Clinical Practice) |
| 17 | Genomics |
| 16 | GxP |
| 16 | AI/ML |
| 15 | Pharmacovigilance |
| 15 | SAP |
| 14 | Quality Assurance |
| 13 | SQL |
| 12 | Veeva |
| 12 | Quality Control |
| 12 | AWS |
| 12 | Workday |
| 10 | HIPAA |
| 8 | Generative AI |
| 8 | Azure |
| 7 | Regulatory Affairs |
| 7 | Bioinformatics |
| 7 | Biostatistics |
| 7 | 21 CFR Part 11 |
| 6 | Salesforce, ServiceNow, GLP, LIMS, Flow Cytometry |
| 5 | ELISA, HPLC, ELN |
| 4 | Mass Spectrometry / LC-MS, NGS |
| 3 | LLM, Kubernetes, NLP, Docker, SDTM, ADaM, CRISPR, qPCR, PowerShell, MATLAB, SAS, CDISC |
4.1 What the Numbers Tell Us
R + Python dominate the statistical-computing stack. R (65) is the top term by a wide margin, with Python (29) at #3. The R:Python ratio is 2.2:1. Compare to generic enterprise data science, where Python usually leads. This is the SAS→R→Python transition still in flight — R remains the language of choice for biostatistics and clinical-data work, with Python emerging for ML and engineering.
Regulatory vocabulary is everywhere. FDA (39), GMP (24), GxP (16), GLP (6), 21 CFR Part 11 (7), Pharmacovigilance (15), Regulatory Affairs (7), Clinical Trials (33), Quality Assurance (14), Quality Control (12), HIPAA (10). The 21 CFR Part 11 / ALCOA+ / data-integrity references in particular signal that regulated content shows up across nearly every job family — not just QA/reg hires. Sample from a CSL posting: “FDA, EMA, EU Annex 11/21 CFR Part 11, and data integrity (ALCOA+)”.
AI/ML is real but pre-inflection. Machine Learning (18), AI/ML (16), Generative AI (8), LLM (3), Deep Learning (1), NLP (3). Total AI-related mentions: ~49 across 258 described jobs (~19%). Generative AI + LLM combined: 11 jobs (4.3%). The “AI replaces drug discovery” thesis is not visible in the hiring data — yet. What IS visible: classic ML roles (ML engineer, ML scientist), with GenAI as an emerging 2026-hire category concentrated at a handful of large pharmas (Eli Lilly, Sanofi, Regeneron) and a few startups (NewLimit, Tamarind Bio-style Forward Deployed Engineer roles).
Sample from an Eli Lilly posting: “Generative AI for drug discovery (foundation-model level); Foundation model training, fine-tuning; LLM evaluation and benchmarking; Cloud-scale ML infrastructure (AWS / Azure / GCP common)”. Sample from a NewLimit posting: “Experience with pooled screening approaches using bulk or single cell read-outs (e.g. CRISPR fitness screens, Perturb/CROP-seq)”.
Cloud is bifurcated. AWS (12) and Azure (8) are real; GCP (18) is mostly Good Clinical Practice (~15 of 18), not Google Cloud Platform. Kubernetes (3), Docker (3), Terraform (2) — DevOps/container signals are thin. Life-sciences runs on validated on-prem + AWS/Azure more than modern K8s stacks.
Enterprise software is locked-in. SAP (15), Veeva (12), Workday (12), Salesforce (6), ServiceNow (6), LIMS (6), ELN (5). These vendors are named explicitly in the JD language — a stable enterprise-software lock-in signal for H2 2026.
Scientific/specialized tools show up where expected. Genomics (17), Bioinformatics (7), Biostatistics (7), Flow Cytometry (6), ELISA (5), HPLC (5), Mass Spectrometry / LC-MS (4), NGS (4), CRISPR (3), qPCR (3), PCR (2), Proteomics (2). The clinical-data stack (CDISC = 3, SDTM = 3, ADaM = 3) is present but not dominant — SAS (3) and the associated CDISC vocabulary are the SAS-Institute-shaped legacy stack.
5. Geographic and Work-Mode Patterns
5.1 Geographic Spread
The largest single concentration outside the Eurofins bucket is Bengaluru, India (176 roles — heavily Eurofins IT roles like .NET-Angular Developer, QA Test Engineer, Senior Software Engineer). Other top locations:
| Location | Roles |
|---|---|
| Bengaluru, India | 176 |
| Lancaster, US | 97 |
| Hamburg, Germany | 49 |
| Lyon, France | 45 |
| Nantes, France | 37 |
| South San Francisco, CA | 33 |
| Toronto, Canada | 32 |
| Ho Chi Minh City, Vietnam | 30 |
| Ivry-sur-Seine, France | 28 |
| Boston, MA | 28 |
| Katowice, Poland | 27 |
| Berlin, Germany | 27 |
| Barneveld, Netherlands | 27 |
| Indaiatuba, Brazil | 25 |
| Brussels, Belgium | 24 |
| Singapore | 23 |
| Rensselaer, NY | 21 |
| Cambridge, MA | 21 |
Reading: the geographic story is “global with US + Western Europe + India concentration.” Eurofins’s Bangalore IT hub drives the India number, but the underlying pattern is consistent: life-sciences hiring is genuinely multinational, with each pharma and CDMO operating site maintaining local-language, local-titled job postings.
5.2 Remote and Hybrid Are Essentially Absent
| Work Mode | Roles |
|---|---|
| Onsite | 3,735 |
| Unspecified | 2,999 |
| Remote | 67 |
| Hybrid | 3 |
Reading: life-sciences hiring in June 2026 is overwhelmingly onsite (97% of tagged roles). Remote roles are <1%. This is consistent with lab/plant/manufacturing dependence — even computational biology, biostatistics, and AI/ML roles, which could plausibly be remote, are tagged Onsite or unspecified in our source data. Either the source data underreports remote availability, or life-sciences employers genuinely aren’t offering remote work at scale in 2026. Likely a mix.
6. Cross-Cutting Observations
6.1 Big Pharma Is Still Hiring in Volume
Roche + Novartis + AstraZeneca + Takeda + Pfizer + Sanofi alone account for ~1,000+ June-active roles across the large-pharma career sites, with AbbVie adding another ~789 through the third-party hiring site mentioned above. Even excluding the AbbVie upper-bound risk, the Big-Pharma hiring footprint in mid-2026 is materially larger than the “biotech slowdown” narrative suggests. The roles being added are specialty-clinical, computational, and supply-chain-modernization — not generic sales/clerical.
6.2 Eurofins Is the Single-Largest Hiring Event in Life Sciences This Month
2,510 unique, deduplicated, geographically-distributed roles is not a normal hiring pattern. Either (a) Eurofins is running a coordinated global capacity-expansion campaign tied to a contract win, (b) they’re backfilling mass turnover, or (c) the listing volume reflects a one-time backlog that will normalize in Q3. Whichever it is, Eurofins is the dominant story in mid-2026 life-sciences hiring.
6.3 Quality and Regulatory Roles Are the Second-Largest Functional Cluster
After lab/testing (driven by Eurofins), Quality Assurance + Quality Control + Regulatory Affairs + Pharmacovigilance together represent ~10% of described-role content. GxP-validated roles are the durable hiring pattern — the regulatory backbone of life sciences stays staffed regardless of capital-cycle fluctuations.
6.4 AI/ML Is Present but Not Dominant
~19% of described jobs mention an AI/ML skill, but Generative AI + LLM combined is only 4.3%. Crucially, the GenAI/LLM roles are concentrated in senior leadership titles (AVP, Sr Director) at Eli Lilly, Sanofi, and Regeneron — strategy-level rather than IC-level. This is consistent with internal capability-building that will surface as IC hiring later in 2026 or 2027. The “AI is replacing drug discovery jobs” thesis is not yet visible in the hiring data.
6.5 R Dominates Python for Statistical Computing
R:Python = 65:29 = 2.2:1 in the described cohort. This is the SAS→R→Python transition still in flight — R remains the language of choice for biostatistics and clinical-data work, with Python emerging for ML and engineering. The classic bio-statistician R+SAS profile is alive and well in 2026.
6.6 Workday Has Won the Big-Pharma Hiring-Systems Battle
Roche, Novartis, AstraZeneca, Takeda, Pfizer, Sanofi, Vertex, Illumina, Qiagen, Tempus, Siegfried, Zoetis, Regeneron, GenScript — every Big-Pharma name in our top 25 publishes its openings through a Workday-powered career site. Other modern hiring platforms (the equivalents used by tech-forward startups) appear primarily at the startup and mid-cap tier. If you’re a Workday recruiter or Workday-integrated services vendor, your TAM is structurally protected for the next 3-5 years.
6.7 Big-Pharma Is Hiring Technical Depth, Not Volume
Sampling the title corpus confirms: Vice President, US Medical Neurology; Therapeutic Area Manager; Technical Development Principal Scientist – Computational Biophysics; Sr Staff Engineer, Synthetic and Bioconjugation Scale-Up Technologies; Senior Manager EDC Development; Senior Manager, Predictive Analytics; Principal Supply Analyst – Kinaxis Maestro. These are specialty, technical, program-specific roles. The “we’re hiring 200 people for the same role” pattern is absent — each Big-Pharma posting is a distinct, narrowly-targeted requisition.
6.8 Remote Is Essentially Dead in Life-Sciences Hiring
70 of 6,804 roles = ~1% Remote-or-Hybrid. This is a structurally-onsite industry. Even computational biology / biostatistics / AI roles — which could plausibly be remote — are tagged Onsite or unspecified in the source data. Treat this as a real constraint when sizing the candidate pool for any life-sciences technical role.
7. What to Watch Over the Next 6 Months
- Whether Eurofins sustains the 2,500+ open-roles level through Q3 — if the listing volume stays this high, it’s a real capacity-expansion story. If it drops to 500 by August, it’s a temporary backlog or a one-off event.
- Whether Big-Pharma maintains 100+ June-active per name — the large-pharma top 10 (Roche, Novartis, AZ, Takeda, Pfizer, Sanofi, Tempus, Illumina, Vertex, Qiagen) all showed 100+ June-active roles. Watch the Big-Pharma career sites through Q3 2026 for sustained volume vs. drawdown.
- Generative-AI / LLM role volume at Eli Lilly, Sanofi, Regeneron, and AbbVie — the GenAI+LLM signal is concentrated at senior leadership titles (AVP, Sr Director) in 2026 H1. If Q3-Q4 2026 sees IC-level GenAI postings expand, the “AI in drug discovery hiring” story is real. If the senior-only concentration persists, the strategy is being built but the IC hiring hasn’t started.
- Workday competitive positioning in Big-Pharma — if a Big-Pharma migrates off its Workday-powered career site in H2 2026, that’s a major industry signal. Watch for M&A-driven hiring-system consolidation.
- CDMO / CRO hiring health — Eurofins’s 2,510 is the data point. If other CDMOs (Catalent, Patheon/PCI, Recipharm, Samsung Biologics) show similar mid-2026 hiring volumes, the contract-manufacturing capacity buildout is a real industry story.
- Vertex’s CF/sickle-cell program expansion — Vertex had 122 June-active roles, and the company’s sickle-cell launch (Casgevy, with CRISPR Therapeutics) is in ramp mode. Watch the Vertex career site through Q3 for program-launch-driven hiring.
- Regeneron’s EDC, Pharmacovigilance, and Predictive-Analytics hiring — Regeneron’s senior-manager-level postings in EDC Development, Pharmacovigilance Operations, and Predictive Analytics signal serious infrastructure investment. Watch for the IC-level postings these senior roles will pull in.
8. The Bottom Line
The mid-2026 life-sciences hiring market is healthier than the prevailing narrative suggests. Big Pharma is hiring in volume — 100+ June-active roles per name across the top 10 large-pharma career sites — and the roles are technically deep, not clerical. AI/ML is real but pre-inflection: present in ~19% of described jobs but concentrated at senior leadership rather than IC level. Eurofins’s 2,510-role hiring campaign is the single biggest story and worth tracking quarter-over-quarter for whether it sustains.
For job seekers: the R/Python biostatistics profile remains in demand, GxP/Quality/Regulatory roles are the durable hiring backbone, and AI/ML hires are happening but mostly at senior levels. For employers: Big-Pharma is buying technical and specialty-clinical talent aggressively — expect compensation pressure in EDC development, biostatistics, computational biology, and pharmacovigilance leadership through H2 2026. For vendors: Workday has structurally won the Big-Pharma career-platform battle; Veeva, SAP, AWS/Azure, and the LIMS/ELN vendors remain the locked-in enterprise-software stack.
The data does not support a “biotech hiring freeze.” It supports a “biotech hiring is now concentrated at the top end of the market, with structurally-onsite, technically-deep, GxP-validated roles dominating.” That is a different, more nuanced story than the headlines.
Sources: Public life-sciences company career pages and hiring listings; 6,804 active June-2026 job postings across 138 companies; keyword-frequency analysis on the 258-posting subset with full descriptions; cross-tabbed by company, source channel, department, location, and seniority. Public-company hiring data is captured at a single point in time and will move with each refresh; treat as directional rather than exact.